DP
NEUP

Diadema Partners’s Neuphoria Therapeutics NEUP Stock Holding History

Diadema Partners’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$194K – 217
2025
Q4 		$194K Buy
50,000
+28,548
+133% +$203K 0.03% 128
2025
Q3 		$253K Buy
+21,452
New +$199K 0.06% 111

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Diadema Partners's NEUP Position: Q1 2026 in Review

Diadema Partners sold out of Neuphoria Therapeutics (NEUP) in Q1 2026, closing a stake of 50,000 shares — an estimated $194K sold.

Diadema Partners first reported a position in NEUP in Q3 2025 and held it in 2 quarters. The position peaked at $253K in Q3 2025. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Diadema Partners reported no remaining Neuphoria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 50,000 Neuphoria Therapeutics shares in Q1 2026, an estimated $194K.
  • Diadema Partners first reported a position in Neuphoria Therapeutics in Q3 2025 and held it in 2 quarters.
  • Diadema Partners's Neuphoria Therapeutics position peaked at $253K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.